Article Text

Download PDFPDF
Decreased cerebrospinal fluid amyloid beta (1–40) levels in frontotemporal lobar degeneration
  1. Y A L Pijnenburg1,
  2. S N M Schoonenboom1,2,
  3. P D Mehta3,
  4. S P Mehta3,
  5. C Mulder2,
  6. R Veerhuis2,
  7. M A Blankenstein2,
  8. P Scheltens1
  1. 1Alzheimer Centre and Department of Neurology, VU University Medical Centre, Amsterdam, the Netherlands
  2. 2Department of Clinical Chemistry, VU University Medical Centre, Amsterdam, the Netherlands
  3. 3Department of Immunology, Institute For Basic Research in Developmental Disabilities, New York, USA
  1. Correspondence to:
 Dr Y A L Pijnenburg
 Alzheimer Centre and Department of Neurology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, the Netherlands; y.pijnenburg{at}


The role of amyloid metabolism in the pathophysiology of frontotemporal lobar degeneration (FTLD) has yet to be elucidated. We compared CSF levels of amyloid beta 1–40 (Aβ40) and amyloid beta 1–42 (Aβ42) in patients with FTLD (n = 21) versus patients with Alzheimer’s disease (AD, n = 39) and in control subjects (n = 30). While in AD cases Aβ42 levels were lower and CSF Aβ40 levels equal to those in controls, a significant decrease in Aβ40 and increase in the CSF Aβ42/Aβ40 ratio was observed in FTLD compared with AD and control subjects. These findings favour a differential involvement of amyloid β peptides in FTLD compared with AD.

  • Aβ40, amyloid beta 1–40
  • Aβ42, amyloid beta 1–42
  • AD, Alzheimer’s disease
  • FTLD, frontotemporal lobar degeneration
  • PS-1, presenilin 1

Statistics from


  • Published Online First 19 March 2007

  • Competing interests: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.